Positron emission tomographic scans in lymphoma: Convention and controversy

Mayo Clinic Proceedings

Volumn 87, Issue 6, 2012, Pages 571-580

  Ansell, Stephen M ^a   Armitage, James O ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ACETIC ACID C 11; BLEOMYCIN; CARBOPLATIN; CHOLINE C 11; CHOLINE F 18; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE; FLUOROTHYMIDINE; IFOSFAMIDE; METHIONINE C 11; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TETRAAZACYCLODODECANETETRAACETIC ACID [1 NA13]OCTREOTIDE GA 68; TRACER; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BONE MARROW; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DRUG DOSE ESCALATION; FEVER; FOLLICULAR LYMPHOMA; GLUCOSE METABOLISM; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; SYSTEMATIC REVIEW; TUMOR REGRESSION;

EID: 84863457697     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.03.006     Document Type: Conference Paper

References (70)

1. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: Prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006; 47(10):1643-1648. (Pubitemid 47545030)
2. Lee TS, Ahn SH, Moon BS, et al. Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol. 2009;36(6):681-686.
3. Nanni C, Fantini L, Nicolini S, Fanti S. Non FDG PET. Clin Radiol. 2010;65(7):536-548.
4. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3=-deoxy-3=-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13(12):3552-3558. (Pubitemid 46955115)
5. André M, Vander Borght T, Bosly A. Interim FDG-PET scan in Hodgkin's lymphoma: Hopes and caveats. Adv Hematol. 2011; 2011:430679.
6. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dosedense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
7. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Riskadapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
8. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
9. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48(10):1626-1632. (Pubitemid 47572710)
10. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator oftherapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47(6):1059-1066. (Pubitemid 46939960)
11. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials [published correction appears in Eur J Nucl Med Mol Imaging. 2008;35(12):2342]. Eur J Nucl Med Mol Imaging. 2008;35(12):2320-2333.
12. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
13. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: Importance of the reference background. J Nucl Med. 2010; 51(12):1857-1862.
14. Fabel M, von Tengg-Kobligk H, Giesel FL, et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV-a feasibility study. Eur Radiol. 2008;18(6):1114-1122.
15. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PETScan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
16. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)FFDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110(3):652-659. (Pubitemid 47106156)
17. Bishu S, Quigley JM, Schmitz J, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48(8):1531-1538. (Pubitemid 47272803)
18. Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol. 2010;195(2):333-340.
19. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685-1690. (Pubitemid 47506256)
20. Cahu X, Bodet-Milin C, Brissot E, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: A study from the GOELAMS group. Ann Oncol. 2011;22(3):705-711.
21. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10): 3875-3876. (Pubitemid 36857861)
22. Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: The experience of a tertiary cancer center. Cancer. 2010;116(6):1454-1461.
23. Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17(3):190-197. (Pubitemid 46963030)
24. Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004;6(6):411-416. (Pubitemid 39618921)
25. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology. 2004;232(3):823-829. (Pubitemid 39100269)
26. Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19(10):1770-1773.
27. Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial. Cancer. 2001;91(5):889-899.
28. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol. 2004;52(1):19-32. (Pubitemid 39195242)
29. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107(1):52-59. (Pubitemid 43053523)
30. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 2001;86(3):266-273. (Pubitemid 32291064)
31. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol. 2004;2(2):115-121.
32. Menzel C, Dobert N, Mitrou P, et al. Positron emission tomography for the staging of Hodgkin's lymphoma-increasing the body of evidence in favor of the method. Acta Oncol. 2002;41(5):430-436. (Pubitemid 35222041)
33. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16(5):337-345. (Pubitemid 34988272)
34. Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)FFDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8): 1139-1143. (Pubitemid 32717828)
35. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-3516. (Pubitemid 350159614)
36. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 2002; 81(1):20-25. (Pubitemid 36075491)
37. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112(4):262-268. (Pubitemid 34219438)
38. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
39. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429-433. (Pubitemid 29323856)
40. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDGPET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(suppl):1147-1150.
41. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001; 115(4):793-800. (Pubitemid 34042895)
42. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternativeto conventional diagnostic methods? J Clin Oncol. 2001; 19(2):414-419. (Pubitemid 32112853)
43. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009; 20(3):503-507.
44. Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194-3200.
45. Engert A, Borchmann P, Pluetschow A, et al. Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavorable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010;116(21):336. [Abstract 765].
46. Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol. 2008;19(suppl): Abstract 052.
47. Holte H, Bogsrud T, Leppa S, et al. 18FDG PET/CT after intensified chemoimmunotherapy in diffuse large B-cell lymphoma (DLBCL), aged 18-65 years with AAIPI 2-3: Positive or indeterminate lesions have a low positive predictive value; A Nordic phase II substudy. Ann Oncol. 2011;22(suppl 4):152 (abstract 224).
48. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol. 2009;27(11):1906-1914.
49. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11): 2678-2687. (Pubitemid 44845624)
50. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
51. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011; 118(15):4053-4061.
52. Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: A clinical and economic analysis. Cancer. 2010;116(16):3835-3842.
53. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90(2):165-171.
54. Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDGPET/ CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Ann Hematol. 2009;88(12):1229-1236.
55. El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center. Leuk Lymphoma. 2011; 52(4):597-603.
56. Chawla SC, Federman N, Zhang D, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: A 5-year retrospective review. Pediatr Radiol. 2010;40(5):681-686.
57. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 1995;36(10):1790-1796.
58. Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20(3):508-512.
59. Bronstein Y, Tummala S, Rohren E. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: Case series and literature review. Clin Nucl Med. 2011;36(2):96-100.
60. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging. 2007;34(5):694-703. (Pubitemid 46669364)
61. Sheng JF, Sheng ZK, Shen XM, et al. Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/ computed tomography in patients with fever of unknown origin. Eur J Intern Med. 2011;22(1):112-116.
62. Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18FFDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: A reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009; 36(11):1813-1821.
63. Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36(5):745-750.
64. Zijlstra JM, Comans EF, van Lingen A, et al. FDG PET in lymphoma: The need for standardization of interpretation: An observer variation study. Nucl Med Commun. 2007;28(10): 798-803. (Pubitemid 47345712)
65. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27(16):2739-2741.
66. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.
67. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin's lymphoma: The importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848-1853.
68. Barnes JA, LaCasce AS, Toomey CE, et al. Early FDG-PET scan predicts outcome in non-bulky limited stage Hodgkin lymphoma, but may not guide use of consolidative radiotherapy. Blood. 2008;112(11):518 (abstract 2453).
69. Friedman DL, Wolden S, Constine L, et al. AHOD0031: A phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood. 2010;116(21):337. [Abstract 766].
70. Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR. Surveillance computed tomography scans for patients with lymphoma: Is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010;10(4):270-277.